Skip to content

Intergrated analysis of proteomics and metabolomics on the efficiency of Modified Erchen Decoction in treating spleen deficiency generating phlegm children with obesity

Intergrated analysis of proteomics and metabolomics on the efficiency of Modified Erchen Decoction in treating spleen deficiency generating phlegm children with obesity

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079919
Enrollment
Unknown
Registered
2024-01-16
Start date
2024-01-18
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity in Children

Interventions

Ttreatment group:Modified Erchen Decoction with interventions in diet, exercise, and sleep
Control group:Interventions in diet, exercise, and sleep
Healthy control group:None

Sponsors

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 13 Years

Inclusion criteria

Inclusion criteria: (1)Diagnostic criteria for Western and Traditional Chinese Medicine mentioned; (2) Age: 7-13 years old; (3) Those who actively cooperate with treatment, complete the course of treatment, and have complete information; (4) The guardian shall sign an informed consent form in accordance with regulations and be able to accept the treatment methods of the child.

Exclusion criteria

Exclusion criteria: (1) Obesity caused by other endocrine disorders, such as hypercortisolism, polycystic ovary syndrome, primary hypothyroidism, and hypothalamic obesity; (2) Individuals with organic lesions such as heart, liver, kidney, and brain, or those with infectious diseases or mental illnesses; (3) Patients with poor compliance and failure to follow up and take medication on time; (4) Those who are unable or unwilling to cooperate with treatment methods, and whose guardians do not agree to sign an informed consent form; (5) Individuals who are currently participating in other clinical trials or have participated in other drug trials in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Fasting insulin;

Secondary

MeasureTime frame
blood lipids;hepatic and renal function;Glucose;

Countries

China

Contacts

Public ContactQingyan Ye

Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine

yeqingyan11@163.com+86 159 2118 8681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026